# Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Source: https://onco.cc/trials/nct05798897/  
OnCo record `nct05798897` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., now recruiting.

## Summary

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma is a phase 1 interventional study registered as NCT05798897 by Marker Therapeutics, Inc., with 79 participants planned, started 2023-01-02. Conditions recorded: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult and Hodgkin's Lymphoma, Relapsed, Adult. Interventions recorded: MT-601.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05798897
- Phase: 1
- Setting: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
- Sponsor: Marker Therapeutics, Inc.
- Enrolled: 79

## Sources

- ClinicalTrials.gov NCT05798897: https://clinicaltrials.gov/study/NCT05798897

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [MT-601](https://onco.cc/drugs/mt-601/)
- companies: [Marker Therapeutics](https://onco.cc/companies/marker-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05798897.json